Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Histologically or cytologically confirmed diagnosis of a relapsed/refractory solid tumor or B-cell lymphoma and meets at least 1 of the following criteria: * Disease progression despite standard therapies * No standard therapies are available or such therapies are not anticipated to result in a durable response * Standard therapies are considered unsuitable or have been refused * Able to take oral medications * Life expectancy \> 12 weeks * For the expansion cohort of the study, all subjects must be confirmed to be positive for ALK gene abnormalities * Subjects with stable brain metastasis will be allowed Exclusion Criteria: * Active central nervous system (CNS) metastases or leptomeningeal involvement as assessed through medical history review and physical examination (dose escalation subjects only) * Known history of a positive test for hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) * Known hereditary or acquired immunodeficiency syndrome or human immunodeficiency virus (HIV) infection * Cardiac arrhythmias \> Grade 1 using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v. 4.03 * Class 3 or 4 New York Heart Association congestive heart failure, acute coronary syndrome, myocardial infarction or cerebrovascular accident within 6 months prior to Cycle 1, Day 1 * Inadequate bone marrow, renal, and/or hepatic function * Confirmed active peptic ulcer disease or history of gastrointestinal bleeding within the past 3 months * Known history of long QT syndrome